Sign up
Pharma Capital

JPMorgan Cazenove gives AstraZeneca shares a boost, hiking its target price to 6,500p from 5,800p

JPMorgan’s analysts said the target hike comes after their updated their numbers to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”
Drugs
They added: “We continue to see double-digit upside to consensus for new launch products in 2018 and 2019"

JPMorgan Cazenove gave a boost to AstraZeneca PLC (LON:AZN) on Thursday, with the drugmaker’s stock shrugging aside ex-dividend factors to push higher as the US bank hiked its target price and reiterated an ‘overweight’ stance.

The bank raised its target for the FTSE 100-listed shares to 6,500p, up from 5,800p previously, with the stock currently trading at 6,079p, up 1.5% on Wednesday’s close.

READ: AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance

In a note to clients, JPMorgan’s analysts said the target hike comes after they updated their numbers for Astra following recent second quarter 2018 results, to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”.

They said: “We continue to see double-digit upside to consensus for new launch products in 2018 and 2019. Overall we make minor near-term forecast changes, with our 2019- 22e Core EPS CAGR unchanged at 19%; however our longer-term growth is further strengthened.”

The analysts noted that they continue to set their price target for AstraZeneca at a 50% premium to large cap-pharma peers, justified by a more than twice as fast medium-term outlook

They concluded: “With our PT implying double-digit upside, and with double-digit upside to consensus new launch expectations this year, as well as upcoming pipeline readouts with attractive risk/reward, we reiterate our Overweight.”



Register here to be notified of future AZN Company articles
View full AZN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.